DANAZOL: AN "OLD-FASHIONED" DRUG FOR A CURRENT PROBLEM IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Riva, M. [1 ]
Crucitti, L. [1 ]
Ravano, E. [1 ]
Nichelatti, M. [1 ]
Reda, G. [2 ]
Cassin, R. [2 ]
Frangi, C. [1 ]
Cairoli, R. [1 ]
Molteni, A. [3 ]
机构：
[1] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[3] ASST Cremona, Cremona, Italy
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C073
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [1] Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective?
    Riva, Marta
    Bosi, Alessandro
    Rizzo, Lorenzo
    Mazzon, Federico
    Ferrari, Silvia
    Lussana, Federico
    Borin, Lorenza
    Castelli, Andrea
    Cairoli, Roberto
    Barcellini, Wilma
    Molteni, Alfredo
    Fattizzo, Bruno
    [J]. HEMASPHERE, 2023, 7 (04):
  • [2] DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE
    Riva, M.
    Ravano, E.
    Cairoli, R.
    Molteni, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 490 - 491
  • [3] Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience
    Riva, Marta
    Crucitti, Lara
    Ravano, Emanuele
    Nichelatti, Michele
    Reda, Gianluigi
    Fiamenghi, Cristina
    Cairoli, Roberto
    Molteni, Alfredo
    [J]. BLOOD, 2018, 132
  • [4] Azacitidine in lower-risk myelodysplastic syndromes
    Santini, Valeria
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
  • [5] Lower-risk myelodysplastic syndromes: Current treatment options for anemia
    Meunier, Mathieu
    Park, Sophie
    [J]. EJHAEM, 2022, 3 (04): : 1091 - 1099
  • [6] Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
    Fenaux, Pierre
    Platzbecker, Uwe
    Mufti, Ghulam J.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Falantes, Jose F.
    Arrizabalaga, Beatriz
    Salvi, Flavia
    Giai, Valentina
    Vyas, Paresh
    Bowen, David
    Selleslag, Dominik
    DeZern, Amy E.
    Jurcic, Joseph G.
    Germing, Ulrich
    Goetze, Katharina S.
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Cluzeau, Thomas
    Voso, Maria-Teresa
    Mazure, Dominiek
    Vellenga, Edo
    Greenberg, Peter L.
    Hellstrom-Lindberg, Eva
    Zeidan, Amer M.
    Ades, Lionel
    Verma, Amit
    Savona, Michael R.
    Laadem, Abderrahmane
    Benzohra, Aziz
    Zhang, Jennie
    Rampersad, Anita
    Dunshee, Diana R.
    Linde, Peter G.
    Sherman, Matthew L.
    Komrokji, Rami S.
    List, Alan F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02): : 140 - 151
  • [7] How to manage lower-risk myelodysplastic syndromes
    Sekeres, M. A.
    [J]. LEUKEMIA, 2012, 26 (03) : 390 - 394
  • [8] Lowering the boom on lower-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Patel, Bhumika J.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 367 - 372
  • [9] Evolving therapies for lower-risk myelodysplastic syndromes
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    [J]. ANNALS OF HEMATOLOGY, 2020, 99 (04) : 677 - 692
  • [10] Management of patients with lower-risk myelodysplastic syndromes
    Andrew M. Brunner
    Heather A. Leitch
    Arjan A. van de Loosdrecht
    Nicolas Bonadies
    [J]. Blood Cancer Journal, 12
12345